Dermapharm Holding Se · XETR:DMP

Dermapharm — Investor Day (November 2022)

48 slides from Dermapharm's investor day presentation, Nov 22, 2022

  1. Slide 1: Capital Markets Day 2022

    Capital Markets Day 2022 22 November 2022

  2. Slide 2: Agenda

    AGENDA 1. Dermapharm Group 2. Marketing approach 3. Allergopharma 4. Euromed 5. Financials Virtual Bankers Information Day 2

  3. Slide 3: 1 Dermapharm Group - Dr. Hans-Georg Feldmeier, CEO

    1 Dermapharm Group - Dr. Hans-Georg Feldmeier, CEO Image: Günther Fotodesign 3

  4. Slide 4: 1.1 Who we are?

    1.1 Who we are? Image: Günther Fotodesign 4

  5. Slide 5: Our experienced and competent management team

    Dermapharm Group Our experienced and competent management team © BPI / Kruppa Dr. Hans-Georg Feldmeier Karin Samusch Dr. Andreas Eberhorn Christof Dreibholz Chief Executive Chief Business Chief Marketing Chief Financial Officer Officer Development Officer Officer Chief Compliance Officer 19 years co

  6. Slide 6: Boarding completed!

    Made in Germany, headquartered in Bavaria Boarding completed! Capital Markets Day 2022 6

  7. Slide 7: Dermapharm at a glance

    Dermapharm at a glance highly attractive and profitable product portfolio … with focus on selected therapeutic areas1 Total Revenue Outlook Mio. € +10-13% CAGR +19.2% 24% 943 794 701 8% Branded pharmaceuticals 231 573 and other healthcare products 467 251 238 244 Revenue split Herbal extracts 243 64

  8. Slide 8: 1.2 Where we are today?

    1.2 Where we are today? Image: Günther Fotodesign

  9. Slide 9: mibe GmbH Arzneimittel milestones

    mibe GmbH Arzneimittel Milestones Total area ~ 80,000 m2 Foundation & start of the new construction of the factory mibe GmbH 2002 Arzneimittel in Brehna Buildings ~ 50,000 m² Production ~10,500 m² Completion factory 1 Laboratory ~2,500 m² 2003 Start of production (ointments, solutions, solid forms)

  10. Slide 10: Pharmaceutical Excellence

    Pharmaceutical Excellence all under one roof with > 700 employees1 Scientific Commercial Quality Logistics Services Sales departments departments control department  Pharmaceutical  Planning  Chemical lab  Technical services  Incoming goods  Order management development  Purchasing  Microbio

  11. Slide 11: Personnel distribution

    Personnel distribution Drug Medical IT safety scientific Analytical Logistics development Technics 2%2% 4% 9% Regulatory Administration 4% Pharmaceutical department 4% development 4% 3% F&E 7% Dispatching Quality 16% L&S 2% Market data management 2% Sales services mibe 696 2% 1% Staff restaurant Fin

  12. Slide 12: R&D philosophy

    R&D philosophy with a highly efficient development process Strong internal R&D capabilities… … to work on specific projects New products 80 40 R&D employees (>13% of all employees)1 Projects 21 Internationalisation 12% 9 51 R&D in % of revenues2 Product maintenance Clinical trial medication Highly e

  13. Slide 13: mibe GmbH Arzneimittel: range of dosage forms

    mibe GmbH Arzneimittel Range of dosage forms Solid forms Liquids/Ointments Sterile forms  Powders  Ointments  Solution for injections  Tablets  Gels  Freeze dried products  Film coated tablets  Creams  Eye drops / ointments  Hard gelatin capsules  Lotions  Liquides Capital Markets Day 20

  14. Slide 14: mibe GmbH Arzneimittel: range of packaging forms

    mibe GmbH Arzneimittel Range of packaging forms Solid forms  Blisters  Tablet container  Sticks Bottles with various dosages, e.g. pipette, spray, dropper Ointments  Liquids/  Tubes  Sticks  Ampoules Sterile Forms  Vials  Ready to fill syringes Capital Markets Day 2022 14

  15. Slide 15: Production quantities 2021

    mibe GmbH Arzneimittel Production quantities 2021 Tablets / Capsules 1,449.1m Blisters 90.1m Ampoules / Vials / Synringes 26.4m Sticks 22.0m Tubes 12.2m Bottles 6.8m Total packs 45.0m Capital Markets Day 2022 15

  16. Slide 16: Increasing productivity through standards and performance control

    Increasing productivity through standards and performance control KPIs Solid Forms Machine Productivity [pcs/h]2 Effectiveness + 33,831 +15% 89,174 55,343 2018 2019 2020 2021 2021 + 507 2018 Standards 2,261 2,768 +12% 297 measures implemented1 2018 2019 2020 2021 1 since project start in 2017; 2 pie

  17. Slide 17: Quality assurance / -control

    mibe GmbH Arzneimittel Quality assurance / -control Quality assurance  QM-Systems  Compliance  Qualification / validation  Documentation Complaint rate 2021: <0.008%  Quality issues Quality control  Testing of active ingredients and other raw materials according to European Pharmacopoeia  Chr

  18. Slide 18: Warehouse and distribution

    mibe GmbH Arzneimittel Warehouse and distribution ~ 27,000 ~ 1,500 ~ 24h Pallet spaces Shipped parcels Pharmacies & hospitals per day supply time 6,000 m2 ~ 45 ~ 48h Consignment spaces Shipped pallets wholesalers per day supply time Capital Markets Day 2022 18

  19. Slide 19: 90% of product portfolio “made in Germany”

    90% of product portfolio “made in Germany” with production of >60m total packs, shipped via central logistic hub in Brehna Tablets/capsules 1,847.4m Blisters 128.0m Sticks 35.9m Strathmann Allergopharma Ampoules/Vials/Syringes 27.2m Bottles 12.3m Tubes 12.2m Trommsdorff Suppository strips 2.0m mibe

  20. Slide 20: Part of solution to the COVID-19 pandemic

    mibe GmbH Arzneimittel – part of solution to the COVID-19 pandemic Step into vaccine production in 2020 BioNTech mibe GmbH Arzneimittel mRNA mRNA Lipid nanoparticles mRNA-production and Formation of lipid nanoparticles Filling the vaccine into vials Cold storage cleaning by combining mRNA and lipids

  21. Slide 21: Rising energy prices as a result of the Ukraine crisis

    Rising energy prices as a result of the Ukraine crisis partly mitigated sustainable reduction in energy consumption at the our production sites Roof top in Brehna Roof Top in Alsdorf  Commissioned 15 May 2021  Planned investment in November 2022  Saving 10% of the electricity consumption  Planne

  22. Slide 22: 1.3 What happened so far in 2022?

    1.3 What happened so far in 2022? Image: adobe stock 399256644, 114372900

  23. Slide 23: Mitigating the COVID-19-pandemic

    Mitigating the COVID-19-pandemic Impact on our business modell with unexpected growth potential in 2021/2022 Safe working environment Production Vaccine production at two sites in Germany Effective protection 1st talks with concepts at all sites BioNtech in No lockdown in critical summer 2020 infras

  24. Slide 24: Integration of AB Cernelle

    Integration of AB Cernelle the founder and leader of extracting pollen for medical use Development of herbal medicines from  A pharmaceutical company with research, development and high-quality pollen extracts and of the API CernitinTM manufacture of drugs in urology, with a special focus on benign

  25. Slide 25: Acquisition of C3 Cannabinoid Compound Company

    Acquisition of C3 Cannabinoid Compound Company an investment in medical cannabis Spectrum Therapeutics GmbH … develops, Production & sales of natural dronabinol … manufactures & Isolation of GMP-compliant pharmaceutical … commercialises quality dronabinol from cannabis flower Neumarkt natural and sy

  26. Slide 26: Goodwill-Impairment of fitvia

    Goodwill-Impairment of fitvia Lessons learned from influencer marketing Leading European digital brand for healthy & functional Business model has not proven sustainable nutrition with a strong sales platform via social media & influencer marketing Expected synergies to other OTC’s and medical devic

  27. Slide 27: Commitment to acquire Arkopharma

    Commitment to acquire Arkopharma a leading producer for food supplements in Western / Southern Europe ArkoPHARMA Fully integrated platform with a unique expertise in plant 1 iconig umbrella brand sourcing, manufacturing and natural product Carros developments >€200m Net Sales 2022e Procurement Resea

  28. Slide 28: 1.4 Introduction to Arkopharma

    1.4 Introduction to Arkopharma – Dr. Andreas Eberhorn, CMO

  29. Slide 29: Arkopharma at a glance

    Arkopharma at a glance Leading producer for food supplements in Western / Southern Europe ArkoPHARMA Fully integrated platform with a unique expertise in plant 1 iconic umbrella brand sourcing, manufacturing and natural product Carros developments > 200 Mio. € Net Sales 2022e Procurement Research &

  30. Slide 30: Strong brand positioning

    Strong brand positioning with significant awareness with the consumer #1 Most bought OTC brand by 1 in 10 French consumers #1 Arkopharma vs. strategic sub-brand awareness #1 Preferred brand Strong loyal consumer base built over the years 1 Arkopharma estimate for 2022 as of August 2022 Capital Marke

  31. Slide 31: Diversified portfolio

    Diversified portfolio built around three main segments… Phytotherapy Natural Health Natural Beauty Phytotherapy is Arkopharma’s Over the years, Arkopharma has Similarly, the Group diversified its historical core business diversified its portfolio with natural portfolio with natural dietary dietary s

  32. Slide 32: Arkopharma sales by therapeutic areas

    Arkopharma sales by therapeutic areas …with 7 strategic sub-brands, representing ~80% of sales CAGR > €200m Chart Title 2019–2022e Become the reference brand for all health 7 Joint +7.7% issues related to joints 20% Roll-out in key geographies through a 6 Urinary +5.5% 5% physician driven model 6% 6

  33. Slide 33: Arkopharma with a large European footprint

    Arkopharma with a large European footprint Total Direct presence 2022e Sales: >€200m FTEs: ~950  2022e Sales: €127m POS: ~32,700 Rest of Europe United Kingdom 62% of total2 Lithuania  FTEs: c.700 2022e Sales: €5m 2% of total  POS1: c.13,600 Netherlands  55% direct Belgium Germany (para)pharmacie

  34. Slide 34: Further internationalisation

    Further internationalisation … and use of product synergies Dermapharm Arkopharma Both companies Capital Markets Day 2022 34

  35. Slide 35: 2 Marketing approach

    2 Marketing approach – Dr. Andreas Eberhorn, CMO

  36. Slide 36: Highly effective sales organisation and strategy

    Highly effective sales organisation and strategy securing customer access and highest number of prescriptions Strong sales force with broad coverage and flexible organisation … … leading to a top 10 pharmaceutical player by units sold in Germany1 1. 173,770 2. 158,865 3. 122,455 Ethical + commercial

  37. Slide 37: Leading branded pharmaceuticals manufacturer

    Leading branded pharmaceuticals manufacturer in selected therapeutic areas Vitamins, Minerals, Food Supplements Pain & Inflammation Dermatology Cardiovascular Support Allergology Gynaecology & Urology Capital Markets Day 2022 37

  38. Slide 38: Leading branded pharmaceuticals manufacturer (1/2)

    Leading branded pharmaceuticals manufacturer in selected therapeutic areas (1/2) YTD YTD CAGR 09.2015 09.2022 Vitamins, Minerals, Food Supplements 10% 14% #1 +11.1% of 93 347 +6.4% 536 €m €m Dermatology 8% #1 +11.3% 14% of 96 416 +3.4% 526 €m €m Allergology 24% 13% +1.5% #3 232 +10.7% 474 of 41 €m €

  39. Slide 39: Leading branded pharmaceuticals manufacturer (2/2)

    Leading branded pharmaceuticals manufacturer in selected therapeutic areas (2/2) YTD YTD CAGR 09.2015 09.2022 Pain & Inflammation #1 19% +5.7% 26% of 52 188 +1.3% 206 €m €m Cardiovascular Support #1 15% +8.9% 20% of 36 103 +4.8% 143 €m €m Gynaecology & Urology 4% 4% -1.0% #10 348 -2.4% 294 of 63 €m

  40. Slide 40: Product Split

    Dermapharm Group Product Split 14% OTC products 64% Rx Majority of our branded pharmaceuticals are prescription products 17% Food supplements / Food supplements for medical purposes 5% Other Source: ApoFusion, Sell-Out Value, 2021 Capital Markets Day 2022 40

  41. Slide 41: Our growth categories

    Our growth categories equally represented by Rx and OTC priority products Vitamins, Minerals, Food Supplements Pain & Inflammation Dermatology Cardiovascular Support Gynaecology & Urology Capital Markets Day 2022 41

  42. Slide 42: Highlights from our key strategic markets

    Highlights from our key strategic markets Growth Driver Market Leadership No.1 No.1 Based on sales growth Based on brand sales rate Unique Products Vaginal mycosis Chronic Pelvic Pain Urinary tract Syndrome infections Source: Galaxy ApoFusion | Sell-Out Umsatz | Zielmarkt | MAT 12/21 Capital Markets

  43. Slide 43: Overview of sell-out performance

    Overview of sell-out performance of our priority products Vitamins Dermatology Pain Cardiovascular Brands (RX / OTC) Market Share 87% 21% 31% 43% 12% 49% 26% 45% Market Position #1 #2 #2 #1 #3 #1 #1 #1 Evolution Index 98 113 N.A. 109 122 104 102 103 Capital Markets Day 2022 43

  44. Slide 44: Calcipotriderm Comp. Gel

    Calcipotriderm Comp. Gel Successful launch after patent expiry (10‘21) Today # 2 in market thanks to fast market entry driven by made in Germany Defined Market Brand Revenues Market Share +14%-pts. -25%-pts. vs. PY vs. PY 6% -4% YoY 14% 9,803 2,887 -9%-pts. 9,380 15% vs. PY 34% -11%-pts. 31% vs. PY

  45. Slide 45: Keltican forte defends brand revenues

    Keltican forte defends brand revenues in decreasing, saturated market resuting in market share expansion Defined Market Brand Revenues Market Share +/-0% +/-0%-pts. -4% 18% YoY vs. PY YoY 43,475 41,705 20,518 20,580 +2%-pts. vs. PY 12% 3% -1%-pts. 49% vs. PY 17% -2%-pts. +2%-pts. vs. PY vs. PY Rest

  46. Slide 46: StroVac has high untapped potential

    StroVac has high untapped potential among unaware sufferers and additional growth potential via StroVac booster High growth potential 3.8m Approx. 80% women frequently ~3m suffer from of sufferers are urinary tract unaware about infections vaccination option ~2% 40,000 bought StroVac in the last 12

  47. Slide 47: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Stat

  48. Slide 48: For information, please contact

    For information, please contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233 Dermapharm FY 2021 48

Dermapharm Holding — Investor Day (November 2022) on 6ix